At the right intensity and treatment duration, aerobic exercise can sharpen thinking skills and improve brain function even in cognitively impaired people, say researchers.
At AAIC, new data on three anti-Aβ antibodies reinforced a sense of hope that Aβ immunotherapy may yet work out. Challenges with each antibody notwithstanding, all four leading candidates, including crenezumab, are now in Phase 3.
Tiny injuries to capillaries in white matter, and to cells in gray matter, have come to be the focus of new imaging measures being explored in early presymptomatic AD.
Regulatory and pharma scientists fielded pleas from families with autosomal-dominant Alzheimer’s disease just prior to the AAIC conference.
Bypass budget promises tide may be turning on an underfunded disease as families with autosomal-dominant Alzheimer’s discuss how to navigate their daily challenges.
A sense of shared purpose energized a day of exchange between families with autosomal-dominant AD and researchers engaged in the Dominantly Inherited Alzheimer Network.
Probing this this Alzheimer’s risk factor, scientists find a novel variant, but no consensus yet on how this cell surface receptor increases risk for disease.
Dose permutations point to synergistic effects on Aβ and amyloid plaques.
A revised plan of action for AD research has emerged from the Alzheimer’s Disease Research Summit 2015.
Scientists find neurodegenerative proteins squirreled away in the skin cells of patients. Could this present an untapped source of biomarkers?
Several different striatal markers may help researchers track early deterioration in Huntington's and Parkinson’s diseases.
A NexGen prevention trial in familial Alzheimer’s mutation carriers will shoot for flexible testing of high doses and drug combinations.
At AD/PD, researchers further tied TREM2 to phagocytosis and enumerated markers that may distinguish beneficial microglia from harmful ones.
Genetic and animal studies hint that B and T cells control amyloid accumulation, though the mechanisms remain unclear.
Researchers link the AD Risk gene BIN1 to tau and amyloid in different model systems, and propose a mechanism for how a PICALM variant might be protective.